SEPN News

Last week, GPCR biotech Septerna (SEPN) plummeted 47% after halting its lead candidate’s Phase 1 trial, just four months after the IPO. It’s far from the only recent biotech IPO to trade down substantially....read more

Renaissance Capital’s October IPO Market Update The fourth quarter kicked off with 22 IPOs raising a combined $3.8 billion in the busiest month for new issuance in nearly three years, despite an end-of-month slowdown ahead of the US presidential election. ...read more

Three sizable IPOs priced this past week, joined by a flurry of small issuers and blank check companies. One scheduled deal did not get done (PRB).Tech distributor Ingram Micro (INGM) priced slightly above the midpoint to raise $409 million at a $5.3...read more

Septerna, a Phase 1 biotech targeting GPCRs in multiple therapeutic areas, raised $288 million by offering 16 million shares at $18, as expected. The company offered 0.7 million more shares than anticipated. It originally planned to offer 10.9 million shares at ...read more